- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00298467
MDX-060 in Patients With Relapsed or Refractory Classic Systemic or Primary Cutaneous Anaplastic Large Cell Lymphoma
An Open-label, Fixed-dose, Multicenter, Phase II Study of MDX-060 in Patients With Relapsed or Refractory Classic Systemic or Primary Cutaneous Anaplastic Large Cell Lymphoma
Studieöversikt
Detaljerad beskrivning
This study is an open-label, fixed-dose, multicenter study of MDX-060 in patients with ALCL who have relapsed or refractory disease. There will be 3 phases of this study: Induction, Maintenance, and Follow-up. Patients will be required to attend all protocol-required visits in the 4-week Induction Phase, in which administration of MDX-060 will occur, as well as other testing. Patients who complete the Induction Phase may be eligible for additional MDX-060 treatment ever 2 months for 1 year in the Maintenance Phase. Patients who complete the Maintenance Phase with a response of stable disease or better will be followed every 2 months for 1 year or until disease progression.
The primary objective of the study is to determine the objective response rate (ORR) at Day 50 in patients with relapsed or refractory classic systemic anaplastic large cell lymphoma (csALCL) or primary cutaneous ALCL (pcALCL) treated with MDX-060. The ORR will be based on an adaption of the NCI Response Criteria for Non-Hodgkin's Lymphoma (NHL) for patients with csALCL and will be based on the Physician's Global Assessment (PGA) for patient with pcALCL.
Secondary objectives include 1) characterizing progression-free survival (PFS); 2) determining response duration (RD); 3) characterizing the effect of MDX-060 on health-related Quality of Life (QoL); 4) evaluating patients with pcALCL using an adaption of the NCI Response Criteria for NHL; 5) characterizing the immunogenicity of MDX-060; 6) characterizing the safety of MDX-060; and 7) determining the best objective response rate (BORR) during the Maintenance Phase of the study.
Studietyp
Inskrivning (Förväntat)
Fas
- Fas 2
Kontakter och platser
Studieorter
-
-
-
Lille, Frankrike, 59037
- Centre Hospitalier Regional Unv. de Lille, Hopital Claude Huriez
-
-
-
-
California
-
Duarte, California, Förenta staterna, 91010
- City of Hope, National Medical Center
-
Fresno, California, Förenta staterna, 93710
- California Oncology of the Central Valley
-
La Jolla, California, Förenta staterna, 92093
- Moores UCSD Cancer Center
-
-
Minnesota
-
Rochester, Minnesota, Förenta staterna, 55905
- Mayo Clinic
-
-
New Jersey
-
New Brunswick, New Jersey, Förenta staterna, 08901
- The Cancer Institute of New Jersey - Robert Wood Johnson Unv. Hosp.
-
-
New York
-
Buffalo, New York, Förenta staterna, 14263
- Roswell Park Cancer Center
-
-
North Carolina
-
Huntersville, North Carolina, Förenta staterna, 28078
- Carolina BioOncology Institute
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- signed informed consent
- confirmed diagnosis of ALCL
- patient with csALCL must be confirmed CD30+
- patients with csALCL must have failed or relapsed following second line (i.e. salvage) chemotherapy or relapsed or failed following autologous stem cell transplant.
- patients with pcALCL must have progressed after treatment with local radiation therapy or surgical excision or failed systemic therapy with a single agent or multi-agent regimen.
- patients with pcALCL must be confirmed CD30+
- ECOG performance of 0 to 2
- at least 12 years of age
- life expectancy 12 weeks or greater
- must meet screening laboratory values
- women must be post-menopausal for at least 1 year; surgically incapable of bearing children; or utilizing a reliable form of contraception. All women must have a negative pregnancy test.
- men must agree to the use of male contraception for the duration of the study
- patients on corticosteroids must be tapered off the medication 2 weeks prior to the first MDX-060 administration and remain off corticosteroids until day 365.
Exclusion Criteria:
- previous treatment with any anti-CD30 antibody
- history of allogenic transplantation
- any tumor lesion 10 cm or greater in diameter
- any other malignancy, excluding basal or squamous cell carcinoma of the skin, or cervical carcinoma in situ. Any cancer from which the patient has been disease free for at least 5 years is permissible.
- any significant acter or chronic infection.
- prior known serum positivity for HIV, hepatitis B or C as determined at screening.
- treatment with an investigational agent within 30 days or 5 half-lives (whichever is longer) of study screening.
- apparent active or latent tuberculosis infection (TB).
- patients who are pregnant or nursing
- any underlying medical condition which, in the investigator's opinion, will make the administration of MDX-060 hazardous or obscure the interpretation of adverse events.
- concomitant chemotherapy, corticosteroids, investigational agents, other anti-ALCL biologics, or radiation therapy
- patients with mycosis fungoides, or
- patients with recurrent, self-healing papulonodular eruptions only or any other lymphoma other than ALCL.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Icke-randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vad mäter studien?
Primära resultatmått
Resultatmått |
---|
Livskvalité
|
säkerhet
|
Objektiv svarsfrekvens
|
Progressionsfri överlevnad
|
Immunogenicitet
|
svarslängd
|
best objective response rate
|
Samarbetspartners och utredare
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- MDX060-04
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Lymfom, storcelligt
-
Second Affiliated Hospital of Guangzhou Medical...Hunan Zhaotai Yongren Medical Innovation Co. Ltd.RekryteringAnti-cancercellsimmunterapi | T Cell och NK CellKina
-
City of Hope Medical CenterNational Cancer Institute (NCI)AvslutadAnaplastiskt storcelligt lymfom | Återkommande mogna T-cell och NK-cell non-Hodgkin lymfom | Refraktärt mogen T-cell och NK-cell non-Hodgkin lymfomFörenta staterna
-
Ohio State University Comprehensive Cancer CenterMerck Sharp & Dohme LLCRekryteringSezary syndrom | Kronisk lymfatisk leukemi | Perifert T-cellslymfom | Primärt kutant T-cell non-Hodgkin lymfom | T-cell prolymfocytisk leukemi | B-cell prolymfocytisk leukemiFörenta staterna
-
City of Hope Medical CenterNational Cancer Institute (NCI)Aktiv, inte rekryterandeRefraktärt mogen T-cell och NK-cell non-Hodgkin lymfom | Mogen T-cell och NK-cell non-Hodgkin lymfom | Återkommande moget T- och NK-cells non-Hodgkin-lymfom | Återkommande kutant T-cell non-Hodgkin lymfom | Refraktärt kutant T-cell non-Hodgkin lymfomFörenta staterna
-
Johnson & Johnson Pharmaceutical Research & Development...AvslutadPure Red-cell AplasiaStorbritannien, Sverige, Sydafrika, Brasilien, Kanada, Tyskland, Norge, Thailand
-
Emory UniversityRekryteringFollikulärt lymfom | Diffust stort B-cellslymfom | Mantelcellslymfom | Kronisk lymfatisk leukemi | Mogen T-cell och NK-cell non-Hodgkin lymfomFörenta staterna
-
Fundación Academia Española de DermatologíaRekryteringLymfom, B-cell | Lymfom, stor B-cell, diffus | Lymfom, B-cell, marginalzon | Lymfom, T-cell, kutan | Sezary syndrom | Lymfom, extranodal NK-T-cellSpanien
-
Assistance Publique - Hôpitaux de ParisHar inte rekryterat ännu
-
Bing HanAvslutadPure Red Cell Aplasia, förvärvadKina
-
University Hospital, BordeauxRekryteringSickle Cell KrisFrankrike, Franska Guyana, Guadeloupe
Kliniska prövningar på MDX-060
-
Bristol-Myers SquibbAvslutadHodgkins sjukdomFörenta staterna
-
Pieris Australia Pty LtdAvslutad
-
Pieris Australia Pty LtdAvslutad
-
DermaGen ABAvslutad
-
DermaGen ABPergamum ABAvslutadAkut otitis externSverige
-
AstraZenecaAvslutad
-
PfizerAvslutad
-
Bristol-Myers SquibbAvslutadNjurcellscancer | Non-hodgkins lymfomFörenta staterna
-
AO GENERIUMRekryteringST Elevation hjärtinfarktRyska Federationen
-
MDx HealthOkändProstatacancerFörenta staterna